Navigation Links
In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
Date:8/5/2010

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection (CDI), nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

The new Physician & Payer Forum report entitled Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals—A Survey of Infectious Disease Specialists, Internists and P&T Committee Members finds that fidaxomicin and, to a higher degree, CDA1/CDB1, will also see robust uptake by surveyed clinicians for the treatment of recurrent CDI. The report also finds that approximately two-thirds of pharmacy and therapeutics committee (P&T) members expect to include fidaxomicin and CDA1/CDB1 on their hospital's formulary.

Fidaxomicin and CDA1/CDB1 would provide much needed options for the treatment of CDI as the only currently available agents in this indication are Pfizer's metronidazole (generically available) and ViroPharma's Vancocin. According to the report, unmet need for novel anti-infectives is shifting away from methicillin-resistant Staphylococcus aureus (MRSA) to CDI and gram-negative infections.

"In addition to MRSA, infectious disease specialists report a rise in CDI and gram-negative infections," said Decision Resources Therap
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
2. WuXi PharmaTech Announces First-Quarter 2010 Results
3. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
4. Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disorders
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. VELOCITY Broadcasting Introduces HD2PC(SM), the First-Ever High-Definition Direct to PC Delivery of Private Broadcast Television
7. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes
8. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
9. Lilly Declares First-Quarter 2010 Dividend
10. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
11. CPG Implements First-Ever Agile PLM Release 9.3 at Avema Pharma Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 /PRNewswire/ ... announced a partnership to expand awareness of proper nutritional ... CFChef Shares program. CFChef Shares will run from August ... CFChef program – an online resource for CF patients ... healthy diet by submitting recipes to the Chef4CF.com ...
(Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
(Date:8/1/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... study evaluating ISIS-SMN Rx in infants with spinal ... infant mortality. Isis plans to dose the first infant ... which time Isis will earn an $18 million milestone ... 3 study, ENDEAR, is the first of several planned ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
... UNION CITY, Calif., Sept. 9, 2011 Abaxis, Inc. ... analysis systems, announced today that Clint Severson, chairman and ... Annual Best Ideas Conference 2011 on Wednesday, September 14, ... held at The Omni Berkshire Place Hotel in New ...
... Inc. (" Valeant ") (NYSE/TSX:VRX), announced today that Valeant mailed ... ") its offer and take-over bid circular in connection with ... all of the outstanding common shares of Afexa (the " ... per Common Share. The Offer expires at 5:00p.m. ...
Cached Medicine Technology:Abaxis, Inc. to Present at CL King's 9th Annual Best Ideas Conference 2011 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 3Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 4
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... manufacturing jobs may have significantly less endurance than those who weigh ... people -- half were obese, half were of normal weight -- ... 60 percent longer. Obesity also was associated with less strength, ... older -- 50 to 65 years of age -- neither improved ...
(Date:8/1/2014)... Ohio In a first-of-its-kind study, researchers at University ... that lap infants may be at greater risk for ... pediatric medical emergencies on flights worldwide between January 2010 ... occurred in children under the age of 2. ... to characterize the rare event of an in-flight pediatric ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 As AndroGel ... the country, Ronald E. Johnson, Jr. has been appointed ... AndroGel and other testosterone medications. Since the Fall of ... P.S.C. have worked diligently to investigate and prosecute the ... embolisms, and blood clots as a result of taking ...
(Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:New research characterizes in-flight pediatric deaths 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
... , 221.10.254.64 COLUMBIA, Mo. Due to changing ... be screened for breast cancer with mammograms, many women ... years and older get a mammogram every year, but ... other year for women older than 50. A University ...
... to help oncologists keep up to date with the ... been launched by the European Society for Medical Oncology ... and news organization. OncologyPRO Oncology Professional ... -- integrating regularly updated oncology news, clinical research, biomarker ...
... An early phase multiple myeloma trial has unexpectedly ... in cells that affect its dose level in the ... Cancer Center Arthur G. James Cancer Hospital and ... conducted the study., Lenalidomide is an anti-inflammatory drug, and ...
... MONDAY, Aug. 8 (HealthDay News) -- Older patients with ... verbal memory impairment, a new study finds. Verbal ... compared heart failure severity and cognitive function -- including ... for potential heart transplantation. Heart failure severity was ...
... features of the influenza virus,s entry point into human ... flu vaccine to protect against a broad range of ... to develop, produce, and distribute a new vaccine for ... Stephen C. Harrison, PhD, chief of the Division of ...
... new source for sexual problems among middle-aged and older ... men,s closest friends. Cornell University and University of ... and the social networks shared by heterosexual men and ... betweenness." In such cases, a man,s female partner has ...
Cached Medicine News:Health News:Doctors, women should spend more time discussing mammograms 2Health News:OncologyPRO -- a revolutionary resource for oncologists 2Health News:Study urges caution with lenalidomide dosage 2Health News:Fine-tuning the flu vaccine for broader protection 2Health News:When a man's female partner becomes too buddy-buddy with his pals, his sex life may suffer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: